There are currently 1184 clinical trials in Pittsburgh, Pennsylvania looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Pittsburgh, University of Pittsburgh Medical Center, Alleghany General Hospital and Children's Hospital of Pittsburgh UPMC. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Improving Measurement and Treatment of Post-stroke Neglect
Recruiting
This study examines how to best assess and treat post-stroke neglect. This study will examine the preliminary effects of an innovative intervention (repetitive task-specific practice + transcranial direct current stimulation) for individuals with neglect. This study will also determine whether items from various neglect assessments can be combined to establish a more comprehensive neglect measure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2024
Locations: VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh, Pennsylvania
Conditions: Stroke
Acoustic Stimulation, Sleep, and Cognitive-Emotional Processes in Young Adults with Anxiety and Depression Symptoms
Recruiting
In this study, the investigators will recruit young adults (ages 18-25 years) with elevated anxiety/depression symptoms and sleep disturbance. Participants will complete two overnights in a sleep lab. During one of the overnights, slow-wave activity will be enhanced by delivering sub-arousal auditory tones during slow-wave sleep using a headband device (Philips SmartSleep or Dreem 2). During the other overnight, tones will not be administered. Cognitive and emotional processes will be evaluated... Read More
Gender:
ALL
Ages:
Between 18 years and 25 years
Trial Updated:
09/12/2024
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Acoustic Stimulation
Promising ROd-cone DYstrophy Gene TherapY
Recruiting
This is a two-step, multicenter, Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm, controlled, double-masked, randomized extension phase (Step 2), in subjects with advanced RCD due to a mutation in the RHO, PDE6A, or PDE6B gene.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/11/2024
Locations: UPMC Eye Center, Pittsburgh, Pennsylvania
Conditions: Retinitis Pigmentosa
Acoustic Waveform Respiratory Evaluation
Recruiting
The study will evaluate the feasibility of using smartphone speakers and microphones to evaluate the caliber of the airways, detect airway obstruction, aid in airway disease diagnosis, and identify disease exacerbations.
Gender:
ALL
Ages:
Between 8 years and 65 years
Trial Updated:
09/11/2024
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Asthma, COPD, Cystic Fibrosis, Ciliary Motility Disorders, Bronchiectasis, Airway Malacia, Healthy Control
First In Human Study of CX-801 in Advanced Solid Tumors
Recruiting
The purpose of this first-in-human study, CTMX-801-101, is to characterize the safety, tolerability, and antitumor activity of CX-801 as monotherapy and in combination with pembrolizumab in adult participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/09/2024
Locations: University of Pittsburgh Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Solid Tumor, Adult
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)
Recruiting
The North American Mitochondrial Disease Consortium (NAMDC) maintains a patient contact registry and tissue biorepository for patients with mitochondrial disorders.
Gender:
ALL
Ages:
All
Trial Updated:
09/03/2024
Locations: Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Mitochondrial Disorders, Mitochondrial Genetic Disorders, Mitochondrial Diseases, Disorder of Mitochondrial Respiratory Chain Complexes, Deletion and Duplication of Mitochondrial DNA
Safety Study of PP-007 in Subjects With Acute Ischemic Stroke
Recruiting
The HEMERA-1 Extension (Part III) is a prospective, open-label, multicenter study to evaluate safety of two doses of PP-007 in Acute Ischemic Stroke (AIS) subjects receiving Intravenous Thrombolysis (IVT) or mechanical thrombectomy (MT) or IVT+MT as standard of care (SOC). Subjects will receive two doses of PP-007 infusion 24 ± 6 hours apart in addition to the site-specific SOC protocol. PP-007 is PEGylated bovine carboxyhemoglobin and will be administered via IV infusion. The effects on collate... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/28/2024
Locations: UPMC Stroke Institute, Pittsburgh, Pennsylvania
Conditions: Acute Ischemic Stroke
High-Risk Veteran Initiative
Recruiting
Veterans at high-risk for hospitalization, including those with complex care needs, represent a large population of VHA patients who often do not receive evidence-based primary care practices that would help them avoid the hospital and improve their health. The high-RIsk VETerans (RIVET) Program will implement evidence-based practices that can support VHA Primary Care teams to deliver more comprehensive and patient-centered care, better strategies to manage medications, and avoid unnecessary hos... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/23/2024
Locations: VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh, Pennsylvania
Conditions: Multimorbidity
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
Recruiting
The purpose of this study is to look at pulmonary exacerbations in people with cystic fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a vein (intravenous or IV). A pulmonary exacerbation is a worsening of respiratory symptoms in people with CF that needs medical intervention. Both doctors and CF patients are trying to understand the best way to treat pulmonary exacerbations. This study is trying to answer the following questions about treating a pulmonar... Read More
Gender:
ALL
Ages:
6 years and above
Trial Updated:
08/23/2024
Locations: Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania
Conditions: Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)
Recruiting
This is a 10-year multi-center, prospective, longitudinal, single arm study evaluating immunologic, inflammatory and laboratory parameters associated with long-term Palynziq treatment in subjects with phenylketonuria (PKU) in the United States (US). Subjects in the US for whom a clinical decision has been made that they will receive pegvaliase to treat their PKU within 30 days following the date of enrollment in Study 165-501 (incident-users) or who have previously started treatment with pegvali... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/23/2024
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Phenylketonuria (PKU)
Detection of Genetic Markers of Lung Cancer
Recruiting
The purpose of this research study is to determine the genetic changes and immunologic changes that are involved in the development and progression of bronchogenic lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/22/2024
Locations: Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Lung Cancer
Safety and Effectiveness of the TENEO 317 Model 2 (1.28 US) Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Hyperopia With or Without Astigmatism
Recruiting
This will be a multicenter, prospective, open label, non-randomized, single arm 12 month study, evaluating the safety and effectiveness of the TECHNOLAS TENEO 317 Model 2 (Software version "1.28 US") excimer laser when used in LASIK surgery to treat hyperopia with or without hyperopic astigmatism. Both eyes of a subject may be enrolled so long as both eyes meet all inclusion/exclusion requirements. Analysis of the primary effectiveness endpoint will be completed at refractive stability.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
08/21/2024
Locations: Site 112, Pittsburgh, Pennsylvania
Conditions: Hyperopia